Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort

(2010) Kiem Oen et al.   ARTHRITIS CARE & RESEARCH

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

(2009) Bénédicte Neven et al.   ARTHRITIS AND RHEUMATISM

Anakinra for Systemic Juvenile Arthritis

(2009) Andrew Zeft et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents

(2009) R. A.G. RUSSO et al.   JOURNAL OF RHEUMATOLOGY

Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist

(2009) Scott Canna et al.   Pediatric Rheumatology

Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis

(2009) Kristen Hayward et al.   ARTHRITIS RESEARCH & THERAPY

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

(2008) C Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES

The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

(2008) Marco Gattorno et al.   ARTHRITIS AND RHEUMATISM

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study

(2008) Norman Ilowite et al.   CLINICAL RHEUMATOLOGY